Navigation Links
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Date:8/23/2007

XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested. Significantly, a single dose of XL880 completely inhibited tumor growth for 21 days in a glioblastoma model.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase 2 and Phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL880 and the timing of the submission of XL880 to GSK. Words such as "expects," "will," "expedite," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and u
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
3. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
7. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
8. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
9. Salix Pharmaceuticals Previews Digestive Disease Week 2007
10. Reatas Synthetic Triterpenoids Profiled in Nature Reviews Cancer
11. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... VEGAS , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... NexGen ® Complete Knee System. ... is the 20 th year since Zimmer first introduced the ... the market. To date, more than five million implantations of the ... year history of the NexGen knee demonstrates the importance of ...
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)... , March 27, 2015 The International ... of myeloma patients while working toward prevention and a ... (D-NY) for introducing a federal resolution (H. Res. 174) ... 2015 as "National Multiple Myeloma Awareness Month." ... myeloma worldwide, and more than 110,000 new cases are ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... (NYSE: HRC ) today announced its fiscal 2010 third quarter dividend of $0.1025 ... 2010 , and is payable on June 30, 2010 , to shareholders of record as ... , ABOUT HILL-ROM ... Hill-Rom is a leading worldwide manufacturer and provider ...
... Cellular Dynamics International, Inc. (CDI), the world,s largest producer ... induced pluripotent stem cells (iPSCs), and iPS Academia Japan, ... seminal iPSC patent portfolio arising out of the work of ... iPS Cell Research and Application (CiRA), Kyoto University ...
Cached Medicine Technology:Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio 2Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio 3Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio 4Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio 5
(Date:3/28/2015)... (PRWEB) March 28, 2015 India ... coverage is made available to all visitors who purchase ... immediately. All members are encouraged to purchase the insurance ... avoid lack of proper coverage for pre-existing medical conditions. ... one or two medical conditions with serious consequences to ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple teams ... according to new research released today at the American Orthopaedic ... “Our findings indicate that a 10 inch increase in height ... history of injury, a 10 mile per hour increase in ... history of injury, and playing for more than one team ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
(Date:3/28/2015)... Mirada, CA (PRWEB) March 28, 2015 ... ear, nose and throat disorders, are now ... is a common issue which is characterized by the ... Affecting 1 in 5 people, tinnitus is a prevalent ... disorder and while it is non-fatal, tinnitus can impede ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... United States are more likely to get screened for ... comparing non-whites living in different parts of the country. ... early online in Cancer , a peer-reviewed journal ... to better understand how colorectal cancer screening disparities develop ...
... noise of the dental drill could spell the end of ... at King,s College London, Brunel University and London South Bank ... known that the sound of the dental drill is the ... avoid trips to the dentist because of it. This new ...
... , FRIDAY, Jan. 7 (HealthDay News) -- The ... stress disorder among those who survived the Sept. 11, 2001 ... the disorder years after. In fact, of the 3,271 ... all (96 percent) said they suffered from at least one ...
... Steven Reinberg HealthDay Reporter , FRIDAY, Jan. 7 ... amount of fluoride in the nation,s drinking water should now ... is a significant help in preventing cavities and tooth decay, ... teeth. About two out of five teens have white spots ...
... drug to treat the underlying disorder instead of the symptoms ... disability, shows some promise according to a new study published ... . Researchers from Rush University Medical Center helped design the ... trial. The data from the early trial of 30 ...
... News) -- The hand gestures you use while talking can ... researchers had volunteers solve a puzzle called the Tower of ... to another. After completing the task the participants talked about ... of hand gestures. The participants then tried the problem ...
Cached Medicine News:Health News:Race affects regional colorectal cancer screening disparities 2Health News:New device set to combat fear of the dentist's drill 2Health News:Many Survivors of World Trade Center Attacks Suffered PTSD: Study 2Health News:U.S. Officials Recommend Reduced Fluoride Levels in Water 2Health News:Study shows promise for new drug to treat Fragile X 2Health News:Gestures May 'Shape' Thoughts 2
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Practice-oriented ophthalmic laser systems for photodisruption....
Medicine Products: